TABLE 1.
Baseline patient characteristics.
| Level | Non-pCR | pCR (n = 32) | p | |
| (n = 76) | ||||
| Age [mean (SD)] | 49.72 (9.76) | 49.09 (12.04) | *0.776 | |
| BMI [mean (SD)] | 23.35 (2.72) | 22.17 (2.54) | *0.044 | |
| ER [mean (SD)] | 67.46 (33.28) | 20.53 (33.72) | *<0.001 | |
| PR [mean (SD)] | 49.34 (33.50) | 30.91 (28.92) | *0.008 | |
| Ki67 [mean (SD)] | 35.04 (21.74) | 55.00 (19.18) | *<0.001 | |
| HER2 (%) | Negative | 52 (68.4) | 13 (40.6) | **0.013 |
| Positive | 24 (31.6) | 19 (59.4) | ||
| Histologic grade (%) | 0-II | 45 (59.2) | 8 (25.0) | **0.002 |
| III | 31 (40.8) | 24 (75.0) | ||
| T stage (%) | I–II | 17 (22.4) | 11 (34.4) | **0.289 |
| III-IV | 59 (77.6) | 21 (65.6) | ||
| Clinical lymph node metastasis | No | 11 (14.5) | 3 (9.4) | **0.684 |
| Yes | 65 (85.5) | 29 (90.6) | ||
| AJCC stage | II | 22 (28.9) | 14 (43.8) | **0.205 |
| III | 54 (71.1) | 18 (56.2) | ||
| HIF1α | High | 42 (66.7) | 21 (33.3) | **<0.001 |
| Low | 18 (40) | 27 (60) |
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; pCR, pathological complete response, *Student’s t-test; **Pearson chi-square test.